Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38227033)

  • 1. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
    Lu S; Zhang W; Wu L; Wang W; Zhang P; ; Fang W; Xing W; Chen Q; Yang L; Mei J; Tan L; Sun X; Xu S; Hu X; Yu G; Yu D; Yang N; Chen Y; Shan J; Xing L; Tian H; Zhang X; Zhou M; Fang H; Wu G; Liu Y; Ye M; Cao L; Jiang J; Li X; Zhu L; Li D; Kang M; Zhong A; Chen K; Wu N; Sun Q; Ma H; Cai K; Wang C; Lin G; Zhu K; Zhang Y; Zhang X; Hu H; Zhang W; Chen J; Yang Z; Hang X; Hu J; Huang Y; Zhang Z; Zhang L; Zhang L; Liu L; Lin D; Zhang J; Chen G; Li Y; Zhu L; Wang W; Yu W; Cao D; Keegan P; Yao S
    JAMA; 2024 Jan; 331(3):201-211. PubMed ID: 38227033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    Wakelee H; Liberman M; Kato T; Tsuboi M; Lee SH; Gao S; Chen KN; Dooms C; Majem M; Eigendorff E; Martinengo GL; Bylicki O; Rodríguez-Abreu D; Chaft JE; Novello S; Yang J; Keller SM; Samkari A; Spicer JD;
    N Engl J Med; 2023 Aug; 389(6):491-503. PubMed ID: 37272513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
    JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
    N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
    Wang Z; Wu L; Li B; Cheng Y; Li X; Wang X; Han L; Wu X; Fan Y; Yu Y; Lv D; Shi J; Huang J; Zhou S; Han B; Sun G; Guo Q; Ji Y; Zhu X; Hu S; Zhang W; Wang Q; Jia Y; Wang Z; Song Y; Wu J; Shi M; Li X; Han Z; Liu Y; Yu Z; Liu AW; Wang X; Zhou C; Zhong D; Miao L; Zhang Z; Zhao H; Yang J; Wang D; Wang Y; Li Q; Zhang X; Ji M; Yang Z; Cui J; Gao B; Wang B; Liu H; Nie L; He M; Jin S; Gu W; Shu Y; Zhou T; Feng J; Yang X; Huang C; Zhu B; Yao Y; Tang X; Yu J; Maher E; Feng H; Yao S; Keegan P; Wang J
    J Clin Oncol; 2023 Jan; 41(3):651-663. PubMed ID: 36206498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM; Spicer J; Lu S; Provencio M; Mitsudomi T; Awad MM; Felip E; Broderick SR; Brahmer JR; Swanson SJ; Kerr K; Wang C; Ciuleanu TE; Saylors GB; Tanaka F; Ito H; Chen KN; Liberman M; Vokes EE; Taube JM; Dorange C; Cai J; Fiore J; Jarkowski A; Balli D; Sausen M; Pandya D; Calvet CY; Girard N;
    N Engl J Med; 2022 May; 386(21):1973-1985. PubMed ID: 35403841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
    Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
    BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    Lei J; Zhao J; Gong L; Ni Y; Zhou Y; Tian F; Liu H; Gu Z; Huang L; Lu Q; Wang X; Sun J; Yang E; Wang T; Zhong D; Wang J; Zhao Z; Liu Z; Wang C; Wang X; Lei G; Yan X; Jiang T
    JAMA Oncol; 2023 Oct; 9(10):1348-1355. PubMed ID: 37535377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
    Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
    JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
    Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
    Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.